Compare Gigacloud Technology Inc (GCT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Sana Biotechnology Inc — how do they compare? Gigacloud Technology Inc trades at $57.1 (market cap $2.02B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Gigacloud Technology Inc is far larger — about 2.4× Sana Biotechnology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Sana Biotechnology Inc for 23 Days on average.
| GCT | SANA | |
|---|---|---|
Market Cap | $2.02B | $836.71M |
Volume | 1,020,985 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $56.42 | $5.92 |
52-Week Low | $25.46 | $2.68 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $2.14B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $55.65, down 0.55% on the day, with a bullish technical outlook from moving averages and a consensus analyst rating of Buy. The stock shows strong fundamentals with a P/E of 13.44, net income margin of 10.65%, and consistent earnings beats in recent quarters. Revenue is projected to grow from $1.29B in 2025 to $1.5B in 2026, while operating cash flow remains robust at $190.66M.
The investment outlook is positive given valuation attractiveness and earnings momentum, but risks include insider selling and reliance on international expansion. Analyst price targets suggest potential upside to $32.50 consensus, though the current price exceeds this, indicating mixed signals. Key catalysts are EU market growth and continued execution against guidance.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
